

# Stefano Bignotti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198250/publications.pdf>

Version: 2024-02-01

31  
papers

1,906  
citations

304368

22  
h-index

433756

31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3055  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq1 1 0.784314 rgBT4Overlo		
2	Neurobiological and clinical effect of metacognitive interpersonal therapy vs structured clinical model: study protocol for a randomized controlled trial. BMC Psychiatry, 2019, 19, 195.	1.1	4
3	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. Psychiatry Research - Neuroimaging, 2019, 283, 118-124.	0.9	33
4	Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatrica Scandinavica, 2016, 133, 63-75.	2.2	20
5	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. PLoS ONE, 2015, 10, e0116686.	1.1	65
6	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. Journal of Affective Disorders, 2015, 183, 179-186.	2.0	17
7	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. Translational Psychiatry, 2015, 5, e687-e687.	2.4	26
8	Abnormalities in Cortical Gray Matter Density in Borderline Personality Disorder. European Psychiatry, 2015, 30, 221-227.	0.1	19
9	Structural brain features of borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2013, 213, 83-91.	0.9	43
10	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.3	197
11	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. Depression and Anxiety, 2013, 30, 1170-1176.	2.0	42
12	Dorsolateral prefrontal transcranial magnetic stimulation in patients with major depression locally affects alpha power of REM sleep. Frontiers in Human Neuroscience, 2013, 7, 433.	1.0	38
13	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. BMC Psychiatry, 2012, 12, 145.	1.1	16
14	Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. Psychiatric Genetics, 2010, 20, 44-45.	0.6	4
15	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters, 2008, 437, 130-134.	1.0	79
16	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of Affective Disorders, 2006, 91, 83-86.	2.0	137
17	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 1-4.	1.1	39
18	Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. Clinical Neurophysiology, 2005, 116, 1062-1071.	0.7	78

#	ARTICLE	IF	CITATIONS
19	Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case-control study. American Journal of Medical Genetics Part A, 2004, 128B, 27-29.	2.4	33
20	3â€² UTR (AGG) <sub>n</sub> repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neuroscience Letters, 2004, 357, 235-237.	1.0	24
21	Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biological Psychiatry, 2003, 53, 617-619.	0.7	57
22	Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophrenia Research, 2003, 60, 47-55.	1.1	100
23	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. Neuropsychobiology, 2002, 46, 17-21.	0.9	27
24	Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. Molecular Psychiatry, 2002, 7, 416-418.	4.1	69
25	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry, 2002, 51, 480-484.	0.7	81
26	Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophrenia Research, 2002, 54, 281-291.	1.1	155
27	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. Psychiatry Research, 2001, 104, 1-9.	1.7	40
28	Abnormal Levels of cAMP-dependent Protein Kinase Regulatory Subunits in Platelets from Schizophrenic Patients. Neuropsychopharmacology, 2000, 23, 216-219.	2.8	36
29	Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. European Neuropsychopharmacology, 2000, 10, 119-124.	0.3	127
30	Depressive symptomatology during clozapine treatment: two case reports. European Neuropsychopharmacology, 1998, 8, 239-240.	0.3	1
31	The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Research, 1998, 32, 9-15.	1.1	297